Evidence map›Paper›PMID 40864337›Full record

Observational studyClinical and experimental nephrology2025

Incidence and risk of cancer emergence among patients post-kidney transplantation in Japan.

Saho Kanno, Tatsuya Noda, Tomoya Myojin, Yuichi Nishioka, Shinichiro Kubo, Masahiro Eriguchi, Ken-Ichi Samejima, Kazuhiko Tsuruya, Tomoaki Imamura

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Clinical and experimental nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Saho KannoDepartment of Public Health, Health Management and Policy, Nara Medical University, 840 Shijyo-Cho, Kashihara City, Nara, 634-8521, Japan.ORCID http://orcid.org/0009-0001-7374-4292
Tatsuya NodaDepartment of Public Health, Health Management and Policy, Nara Medical University, 840 Shijyo-Cho, Kashihara City, Nara, 634-8521, Japan. noda@naramed-u.ac.jp.ORCID http://orcid.org/0000-0002-3652-7547
Tomoya MyojinDepartment of Community Health and Preventive Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Chuo-Ku, Hamamatsu, Shizuoka, 431-3192, Japan.
Yuichi NishiokaDepartment of Public Health, Health Management and Policy, Nara Medical University, 840 Shijyo-Cho, Kashihara City, Nara, 634-8521, Japan.
Shinichiro KuboDepartment of Public Health, Health Management and Policy, Nara Medical University, 840 Shijyo-Cho, Kashihara City, Nara, 634-8521, Japan.
Masahiro EriguchiDepartment of Nephrology, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634-8521, Japan.
Ken-Ichi SamejimaDepartment of Nephrology, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634-8521, Japan.
Kazuhiko TsuruyaDepartment of Nephrology, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634-8521, Japan.
Tomoaki ImamuraDepartment of Public Health, Health Management and Policy, Nara Medical University, 840 Shijyo-Cho, Kashihara City, Nara, 634-8521, Japan.

Funding

Japan Society for the Promotion of Science 19K19464Japan Society for the Promotion of Science 22H03355Japan Society for the Promotion of Science 23K24613Japan Society for the Promotion of Science 24K22341Japan Society for the Promotion of Science JP20H00623Ministry of Health, Labour and Welfare 24FC2004
6 · The paper itself

Abstract

backgroundCancer is one of the most common complications after kidney transplantation and an important cause of mortality. However, no large, nationally representative study has investigated cancer incidence post-kidney transplantation. This study aimed to determine the standardized incidence ratio (SIR) for cancer after kidney transplantation using the National Database of Health Insurance Claims (NDB).

methodsWe used NDB from April 2013 to March 2022; patients were included if they had been on dialysis for at least one year, were diagnosed with cancer related to post-kidney transplantation, and were prescribed immunosuppressant drugs in FY2014 or FY2015. We defined patients with cancer as those who were coded as ICD-10 for cancer in FY2016 or later. The number of patients and SIRs were tabulated according to the duration after kidney transplantation and cancer type.

resultsThe total number of patients was 4484 (males: 2879; females: 1605). The SIRs of all cancers from the first to the seventh year after kidney transplantation were 232/291/235/248/257/187/149, respectively, showing a gradual downward trend over time. The predilection sites of cancer in both men and women were post-transplant lymphoproliferative disease, Kaposi sarcoma, and the kidney.

conclusionThis observational study, which followed over 100 million people, is the first large-scale research to track kidney transplant recipients for under 10 years. It incorporates an unprecedented sample size and uniquely identified short-term cancer risk trends following kidney transplantation.

Indexed as

Kidney TransplantationNeoplasmsAdultAgedDatabases, FactualFemaleHumansImmunosuppressive AgentsIncidenceJapanMaleMiddle AgedRisk AssessmentRisk FactorsTime FactorsYoung AdultImmunosuppressive AgentsAdministrative claims database-NDB-national databaseKidney transplantationPost-transplant cancerStandardized incidence ratio

Identifiers

PMID40864337
PMCPMC12660435

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.